Cooper Companies (NASDAQ:COO) Issues FY 2026 Earnings Guidance

Key Points

• Cooper Companies issued below-consensus FY 2026 guidance: adjusted EPS is expected at $4.51–$4.55 versus the $4.63 analyst consensus, while revenue guidance of $4.2–$4.3 billion reaches consensus only at the high end.
• Fourth-quarter earnings guidance also fell short at $1.05–$1.09 per share, indicating potential pressure on margins, costs, or product mix.
• Shares fell 6.2% to $63.48 following the update. Separately, CooperCompanies completed its strategic review, retained CooperSurgical, and increased its share-repurchase authorization from $2 billion to $3 billion.

Cooper Companies (NASDAQ:COO - Get Free Report) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 4.510-4.550 for the period, compared to the consensus EPS estimate of 4.630. The company issued revenue guidance of $4.2 billion-$4.3 billion, compared to the consensus revenue estimate of $4.3 billion. Cooper Companies also updated its Q4 2026 guidance to 1.050-1.090 EPS.

Analysts Set New Price Targets

A number of brokerages have recently commented on COO. KeyCorp reiterated a "sector weight" rating on shares of Cooper Companies in a research report on Friday, June 5th. Wall Street Zen upgraded Cooper Companies from a "hold" rating to a "buy" rating in a report on Sunday, June 21st. Needham & Company LLC cut their target price on Cooper Companies from $101.00 to $86.00 and set a "buy" rating on the stock in a research report on Friday, June 5th. Citigroup restated a "neutral" rating and set a $80.00 price target (up from $76.00) on shares of Cooper Companies in a report on Thursday, August 13th. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of Cooper Companies in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have given a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $81.64.

Cooper Companies Stock Down 6.2%

COO traded down $4.21 on Wednesday, reaching $63.48. 8,383,881 shares of the company traded hands, compared to its average volume of 2,347,124. The company has a market cap of $12.38 billion, a price-to-earnings ratio of 53.80, a PEG ratio of 1.82 and a beta of 0.82. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.27 and a quick ratio of 0.78. The stock's 50 day moving average price is $72.59 and its 200-day moving average price is $70.17. Cooper Companies has a 52-week low of $58.89 and a 52-week high of $89.83.

Cooper Companies (NASDAQ:COO - Get Free Report) last posted its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.12 by $0.03. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, sell-side analysts expect that Cooper Companies will post 4.63 EPS for the current fiscal year.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies increased its share-repurchase authorization from $2 billion to $3 billion. The larger buyback could support earnings per share and signal that management views the stock as undervalued. The company also said its board remains open to other value-creation options. CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
• Neutral Sentiment: CooperCompanies completed its strategic review and unanimously decided to retain CooperSurgical. While the decision removes uncertainty around the business, it also means the company will not receive a potential near-term cash infusion from a sale or separation. CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
• Neutral Sentiment: The company released fiscal third-quarter 2026 results for the period ended July 31. The supplied announcement does not include the reported revenue or earnings figures, so the market’s reaction is likely being driven primarily by the forward guidance. CooperCompanies Announces Third Quarter 2026 Results
• Negative Sentiment: Fiscal 2026 adjusted EPS guidance of $4.51–$4.55 is below the consensus estimate of $4.63. Revenue guidance of $4.2–$4.3 billion is also below or only reaches the $4.3 billion consensus at the high end, suggesting weaker-than-expected growth or profitability.
• Negative Sentiment: Fourth-quarter 2026 EPS guidance of $1.05–$1.09 is well below the $1.20 consensus estimate. Although revenue guidance of approximately $1.1 billion is broadly in line with expectations, the earnings shortfall indicates pressure on margins, costs, or the business mix.

Institutional Trading of Cooper Companies

A number of institutional investors have recently added to or reduced their stakes in the business. CYBER HORNET ETFs LLC acquired a new position in shares of Cooper Companies during the 2nd quarter worth $36,000. MUFG Securities EMEA plc acquired a new stake in Cooper Companies in the 2nd quarter worth approximately $42,000. IFP Advisors Inc boosted its position in Cooper Companies by 2,647.8% during the third quarter. IFP Advisors Inc now owns 632 shares of the medical device company's stock worth $43,000 after purchasing an additional 609 shares during the period. Johnson Financial Group Inc. bought a new position in shares of Cooper Companies in the third quarter valued at approximately $59,000. Finally, Quarry LP acquired a new stake in shares of Cooper Companies in the fourth quarter worth $70,000. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Cooper Companies Company Profile

Cooper Companies, Inc NASDAQ: COO is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women's health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.